Journal News

How to catch an HIF

Gregg Semenza’s lab and hypoxia-inducible factor 1
Martin J. Spiering
January 10, 2020

Every animal cell needs molecular oxygen to survive and do its job. Because skin, tissues and organs block most oxygen diffusion directly from the air, molecular oxygen concentrations inside the body often are less than 5%, much lower than the 21% in Earth’s atmosphere.

As multicellular organisms evolved, this steep oxygen gradient necessitated the development biochemical mechanisms that monitor and control oxygen levels in the body.

Gregg Semenza and his lab at the Johns Hopkins University School of Medicine purified and biochemically characterized HIF-1 in the mid-1990s, a milestone in uncovering its pivotal role in oxygen sensing.

A major player in sensing potentially harmful drops in cellular oxygen concentrations, or hypoxia, is the transcription factor hypoxia-inducible factor 1. HIF-1 and its close relative HIF-2 regulate many genes, including the erythropoietin, or EPO, gene, which encodes a hormone that stimulates production of red blood cells.

Catching Hif

Gregg Semenza and his lab at the Johns Hopkins University School of Medicine purified and biochemically characterized HIF-1 in the mid-1990s, a milestone in uncovering its pivotal role in oxygen sensing and part of the work that earned Semenza a 2019 Nobel Prize. The two Journal of Biological Chemistry papers reporting that early work are recognized as Classics.

“JBC was the first choice,” Semenza said of the decision where to publish the first paper, “to me, that was a classic JBC paper.”

A few years before identifying HIF-1, Semenza’s team had found that hypoxia induces the binding of a protein to an enhancer of the EPO gene. Although the researchers could pinpoint the DNA region that is bound by the hypoxia-induced protein, the protein’s identity was unknown, prompting Semenza to look for it.

Semenza’s team first had to cross some unexpectedly rough waters. “We used an expression cloning strategy,” he said. The researchers expressed human proteins from       cDNAs in bacteriophages and used the HIF-binding oligonucleotide to find proteins binding to it. “We screened millions and millions of clones and got nothing.”

Semenza and his team were undeterred. “We could give up and let someone else do it — but that didn’t sound like a good idea,” he said. 

The gene encoding the erythropoietin protein, shown here, was the first known target of the transcription factor HIF isolated by Gregg Semenza and colleagues.

They changed tack, embarking on a biochemical purification that involved growing HeLa cells in large cultures, exposing them to hypoxia, preparing protein extracts from them and purifying HIF-1 via chromatography.

The authors could show that purified HIF-1 has two subunits: a larger one of 120 kilodaltons, called HIF-1 alpha, and a smaller one of 91 to 94 kilodaltons, called HIF-1 beta. 

The purification yielded enough protein of the two HIF-1 subunits for amino acid microsequencing that gave short protein sequences the researchers could use to identify the full-length sequences of the HIF-1 subunits.

These sequences showed that both HIF-1 subunits belong to a group of transcription factors containing a motif required for dimerization and DNA binding and a domain for interactions with other proteins.

The HIF-1 beta sequence was identical to that of a previously identified protein, aryl hydrocarbon receptor nuclear translocator, known as ARNT, a subunit of the dioxin receptor, which senses dioxins and other toxic chemicals. However, the HIF-1 alpha sequence was unknown previously and only partially similar to single-minded homolog, a transcription factor in Drosophila.

The second Classics paper helped define the regions in the two HIF-1 subunits required for their dimerization, DNA binding and activation of transcription of hypoxia-induced genes.

What might look now like a series of straightforward steps of purifying and sequencing a protein was an exercise in continual improvisation.

“My lab was a molecular genetics laboratory,” Semenza said. “We didn’t even own a fraction collector.” 
Luckily for Semenza, the lab of another Johns Hopkins researcher, Thomas Kelly, was just across the street.

“Tom was one of the first people to purify a protein based on its binding to DNA,” Semenza said. “We couldn’t have (isolated HIF-1) without the help from Tom Kelly’s lab.”

A ubiquitous factor

The biochemical characterization of HIF-1 threw open the doors to many additional studies from Semenza’s group and other labs. 

These investigations showed that the specific HIF-1 binding site is ubiquitous in the human genome. This hinted at HIF-1’s role as the hub of metabolic regulation in response to oxygen.

“These genes are not induced by hypoxia in every cell type under every condition,” Semenza said. “They’re induced by hypoxia in some cell types under some conditions — the plasticity of the (hypoxic) response is remarkable.”

The HIF-1-regulated genes encode proteins in many metabolic processes, including glycolysis, angiogenesis and wound healing. They also are upregulated when people move from lower to higher altitudes, and they are hyperactive in some diseases, most notably cancer. HIF-mediated signaling is now a therapeutic target to combat cancer and manage disorders such as altitude sickness.

Specific prolyl-4-hydroxylase domain, or PHD, proteins regulate HIF-1’s activity. In the presence of normal oxygen concentration, the PHDs modify two conserved proline residues in HIF-1 alpha, leading to binding by the von Hippel–Lindau protein, which targets HIF-1 alpha for degradation.
“So (cells) make HIF1alpha, but it’s being degraded when oxygen is available,” Semenza said. 

Limiting oxygen levels inhibits the PHD proteins, increasing the fraction of HIF-1 alpha that’s not hydroxylated. This stabilizes the HIF-1 protein, causing its accumulation and leading to the activation of its target genes.

“It is a really beautiful system,” Semenza said.

In addition to the 2019 Nobel Prize in physiology or medicine, which he shared with two other physician–scientists, William Kaelin Jr. and Peter Ratcliffe, Semenza received the Albert Lasker Award for Basic Medical Research in 2016 for his work on the role of HIF-1 in oxygen sensing.

Read more Journal of Biological Chemistry Classics at

Martin J. Spiering

Martin J. Spiering is the technical editor at the Journal of Biological Chemistry.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

From the journals: JBC
Journal News

From the journals: JBC

July 14, 2020

A metal ion that transforms tau. A new target to take out cancer cells. One substitution that abolishes enzyme allostery. Read about recent papers on these topics and more in the Journal of Biological Chemistry.

COVID-19 retractions show that the science is working as it should
Life in the Lab

COVID-19 retractions show that the science is working as it should

July 12, 2020

Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science's normal process of self-correction, explains Mark R. O’Brian.

In the future, lab mice will live in computer chips, not cages
Life in the Lab

In the future, lab mice will live in computer chips, not cages

July 11, 2020

As COVID-19 shuttered laboratories across the U.S., many researchers were forced to euthanize the animals they study. Lindsay Gray, a rodent surgeon in an animal research lab that faced this dilemma, argues here there is a safer, more effective way.

Proteomics reveals hallmarks of aging in brain stem cells
Journal News

Proteomics reveals hallmarks of aging in brain stem cells

July 09, 2020

Early in adulthood, the brain regenerates lost myelin effectively, but remyelination falters with age. Researchers seek to understand why — and what the change may mean for people with multiple sclerosis.

Ocean virus hijacks carbon-storing bacteria
Journal News

Ocean virus hijacks carbon-storing bacteria

July 07, 2020

A Journal of Biological Chemistry paper reports that these minuscule interactions could have ripple effects on global carbon dioxide levels.

CRISPR nanoparticles are the next big hope in Alzheimer’s disease treatments

CRISPR nanoparticles are the next big hope in Alzheimer’s disease treatments

July 04, 2020

Nearly 6 million Americans live with Alzheimer’s disease without solid treatment options.